Short answer
Enliven Therapeutics, Inc. (ELVN) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$28M
- −37.5% YoY · +14.7% QoQ
- EPS (diluted)
- −$0.34
- −13.3% YoY · +30.6% QoQ
Source: XBRL data from the Enliven Therapeutics, Inc. (ELVN) Q3 2026 10-Q on SEC EDGAR. USD.
Enliven Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product or other revenue
- Operating margin not applicable, operating loss $36.0M vs $25.1M YoY
- Relcobatinib R&D $12.0M vs $4.7M, strongest program; ELVN-002 $1.0M vs $2.3M
- Cash, equivalents and securities $884.4M; operating cash use $50.4M for nine months
- 2026 Public Offering net proceeds $432.8M; funding sufficient for at least 12 months, additional capital needed thereafter
Risk Factors
- Newly emphasized FDA disruption risk triggered by agency layoffs, reorganization and budget constraints, potentially delaying reviews and inspections
- Most materially updated pricing risk, CMS GLOBE Model Final Rule requires international-price-linked Part B rebates beginning April 1, 2027
- Companion-diagnostic compliance risk, FDA LDT rule litigation may alter validation, labeling and reimbursement requirements
- Near-term clinical risk, CML enrollment constrained by Scemblix approval and competing trials
- Financial risk, $83.8 million nine-month net loss and $431.0 million accumulated deficit underscore continued capital needs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Enliven Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.